Clinical immunohistochemistry indicated that tumors with higher HDAC1 accompanied with lower OAZ1 expression may show a poor response to platinum treatment and poorer prognosis than tumors with other expression patterns in patients with NSCLC. Here, HDAC1 is linked to non-small cell lung carcinoma.